Main variables;Main activity, secondary one or a tool necessary for production;Total
Companies that carry out R&D in Biotechnology;Total;1,348
Companies that carry out R&D in Biotechnology;Main;661
Companies that carry out R&D in Biotechnology;Secondary dwellings;188
Companies that carry out R&D in Biotechnology;Tool;500
%Companies according to biotechnology used: Genetic code;Total;31.0
%Companies according to biotechnology used: Genetic code;Main;40.3
%Companies according to biotechnology used: Genetic code;Secondary dwellings;25.2
%Companies according to biotechnology used: Genetic code;Tool;21.0
%Companies according to biotechnology used: Functional units;Total;38.4
%Companies according to biotechnology used: Functional units;Main;45.9
%Companies according to biotechnology used: Functional units;Secondary dwellings;37.6
%Companies according to biotechnology used: Functional units;Tool;28.8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;21.7
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Main;27.3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Secondary dwellings;15.9
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Tool;16.5
%Companies according to biotechnology used: Bioprocesses;Total;50.3
%Companies according to biotechnology used: Bioprocesses;Main;40.9
%Companies according to biotechnology used: Bioprocesses;Secondary dwellings;53.3
%Companies according to biotechnology used: Bioprocesses;Tool;61.7
%Companies according to biotechnology used: Sub-cellular organisms;Total;8.2
%Companies according to biotechnology used: Sub-cellular organisms;Main;12.1
%Companies according to biotechnology used: Sub-cellular organisms;Secondary dwellings;3.3
%Companies according to biotechnology used: Sub-cellular organisms;Tool;5.0
%Companies according to biotechnology used: Bio-computing;Total;24.1
%Companies according to biotechnology used: Bio-computing;Main;33.8
%Companies according to biotechnology used: Bio-computing;Secondary dwellings;20.2
%Companies according to biotechnology used: Bio-computing;Tool;12.9
%Companies according to biotechnology used: Nanobiotechnology;Total;11.8
%Companies according to biotechnology used: Nanobiotechnology;Main;15.9
%Companies according to biotechnology used: Nanobiotechnology;Secondary dwellings;14.0
%Companies according to biotechnology used: Nanobiotechnology;Tool;5.4
%Companies according to biotechnology used: Other;Total;16.4
%Companies according to biotechnology used: Other;Main;18.4
%Companies according to biotechnology used: Other;Secondary dwellings;20.3
%Companies according to biotechnology used: Other;Tool;12.3
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;45.8
%Company by field(s) of ultimate application of biotechnology use: Human Health;Main;64.5
%Company by field(s) of ultimate application of biotechnology use: Human Health;Secondary dwellings;32.2
%Company by field(s) of ultimate application of biotechnology use: Human Health;Tool;26.3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;15.3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Main;17.2
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Secondary dwellings;14.5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Tool;12.9
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;31.5
%Company by field(s) of ultimate application of biotechnology use: Food products;Main;21.1
%Company by field(s) of ultimate application of biotechnology use: Food products;Secondary dwellings;34.9
%Company by field(s) of ultimate application of biotechnology use: Food products;Tool;44.1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;23.7
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Main;19.9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Secondary dwellings;32.9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Tool;25.2
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;15.5
%Company by field(s) of ultimate application of biotechnology use: Environment;Main;14.1
%Company by field(s) of ultimate application of biotechnology use: Environment;Secondary dwellings;25.4
%Company by field(s) of ultimate application of biotechnology use: Environment;Tool;13.7
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;13.4
%Company by field(s) of ultimate application of biotechnology use: Industry;Main;14.3
%Company by field(s) of ultimate application of biotechnology use: Industry;Secondary dwellings;19.1
%Company by field(s) of ultimate application of biotechnology use: Industry;Tool;10.1
Personnel in R&D in biotechnology (no. of persons);Total;15,744
Personnel in R&D in biotechnology (no. of persons);Main;8,573
Personnel in R&D in biotechnology (no. of persons);Secondary dwellings;1,786
Personnel in R&D in biotechnology (no. of persons);Tool;5,385
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total;8,380
Personnel in R&D in biotechnology (no. of persons): Research personnel;Main;5,028
Personnel in R&D in biotechnology (no. of persons): Research personnel;Secondary dwellings;952
Personnel in R&D in biotechnology (no. of persons): Research personnel;Tool;2,400
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total;7,364
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Main;3,545
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Secondary dwellings;834
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Tool;2,985
Personnel in R&D in biotechnology (no. of persons). Women;Total;8,725
Personnel in R&D in biotechnology (no. of persons). Women;Main;4,985
Personnel in R&D in biotechnology (no. of persons). Women;Secondary dwellings;952
Personnel in R&D in biotechnology (no. of persons). Women;Tool;2,788
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total;4,521
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Main;2,794
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Secondary dwellings;504
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Tool;1,223
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total;4,204
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Main;2,191
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Secondary dwellings;448
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Tool;1,565
Personnel in R&D in biotechnology (FTE);Total;11,523.2
Personnel in R&D in biotechnology (FTE);Main;6,809.8
Personnel in R&D in biotechnology (FTE);Secondary dwellings;1,008.1
Personnel in R&D in biotechnology (FTE);Tool;3,705.3
Personnel in R&D in biotechnology (FTE): Research personnel;Total;6,341.6
Personnel in R&D in biotechnology (FTE): Research personnel;Main;4,061.4
Personnel in R&D in biotechnology (FTE): Research personnel;Secondary dwellings;628.5
Personnel in R&D in biotechnology (FTE): Research personnel;Tool;1,651.7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total;5,181.6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Main;2,748.4
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Secondary dwellings;379.7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Tool;2,053.6
Personnel in R&D in biotechnology (FTE). Women;Total;6,552.7
Personnel in R&D in biotechnology (FTE). Women;Main;4,019.9
Personnel in R&D in biotechnology (FTE). Women;Secondary dwellings;569.1
Personnel in R&D in biotechnology (FTE). Women;Tool;1,963.7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total;3,464.4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Main;2,258.6
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Secondary dwellings;349.8
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Tool;855.9
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,088.3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1,761.3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary dwellings;219.3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Tool;1,107.7
Internal expenditure on R&D (thousands of euros);Total;1,037,887
Internal expenditure on R&D (thousands of euros);Main;643,053
Internal expenditure on R&D (thousands of euros);Secondary dwellings;81,049
Internal expenditure on R&D (thousands of euros);Tool;313,785
1) By nature of the expense: Current expenses;Total;939,471
1) By nature of the expense: Current expenses;Main;569,179
1) By nature of the expense: Current expenses;Secondary dwellings;76,172
1) By nature of the expense: Current expenses;Tool;294,120
1.1) Remuneration to research personnel;Total;321,525
1.1) Remuneration to research personnel;Main;206,505
1.1) Remuneration to research personnel;Secondary dwellings;32,639
1.1) Remuneration to research personnel;Tool;82,382
1.2) Remuneration to technicians and auxiliary personnel;Total;194,656
1.2) Remuneration to technicians and auxiliary personnel;Main;105,018
1.2) Remuneration to technicians and auxiliary personnel;Secondary dwellings;12,981
1.2) Remuneration to technicians and auxiliary personnel;Tool;76,658
1.3) Other current expenses;Total;423,290
1.3) Other current expenses;Main;257,656
1.3) Other current expenses;Secondary dwellings;30,553
1.3) Other current expenses;Tool;135,081
2) By nature of the expense: Capital expenses;Total;98,416
2) By nature of the expense: Capital expenses;Main;73,874
2) By nature of the expense: Capital expenses;Secondary dwellings;4,877
2) By nature of the expense: Capital expenses;Tool;19,664
2.1) Land and buildings;Total;10,150
2.1) Land and buildings;Main;7,449
2.1) Land and buildings;Secondary dwellings;600
2.1) Land and buildings;Tool;2,102
2.2) Equipment and instruments;Total;72,538
2.2) Equipment and instruments;Main;53,214
2.2) Equipment and instruments;Secondary dwellings;3,495
2.2) Equipment and instruments;Tool;15,828
2.3) Acquisition of specific R+D software;Total;5,713
2.3) Acquisition of specific R+D software;Main;4,293
2.3) Acquisition of specific R+D software;Secondary dwellings;369
2.3) Acquisition of specific R+D software;Tool;1,051
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;10,015
2.4) Otros productos de propiedad intelectual específicos para I+D;Main;8,918
2.4) Otros productos de propiedad intelectual específicos para I+D;Secondary dwellings;413
2.4) Otros productos de propiedad intelectual específicos para I+D;Tool;684
1.1) By origin of the funds: Own funds;Total;711,037
1.1) By origin of the funds: Own funds;Main;412,945
1.1) By origin of the funds: Own funds;Secondary dwellings;55,579
1.1) By origin of the funds: Own funds;Tool;242,513
1.2) By origin of the funds: From companies;Total;121,595
1.2) By origin of the funds: From companies;Main;82,588
1.2) By origin of the funds: From companies;Secondary dwellings;8,576
1.2) By origin of the funds: From companies;Tool;30,431
1.3) By origin of the funds: Public Administration funds;Total;107,422
1.3) By origin of the funds: Public Administration funds;Main;66,483
1.3) By origin of the funds: Public Administration funds;Secondary dwellings;11,401
1.3) By origin of the funds: Public Administration funds;Tool;29,539
1.4) By origin of the funds: From Universities;Total;192
1.4) By origin of the funds: From Universities;Main;68
1.4) By origin of the funds: From Universities;Secondary dwellings;14
1.4) By origin of the funds: From Universities;Tool;111
1.5) By origin of the funds: From non profit private institutions;Total;10,756
1.5) By origin of the funds: From non profit private institutions;Main;9,444
1.5) By origin of the funds: From non profit private institutions;Secondary dwellings;0
1.5) By origin of the funds: From non profit private institutions;Tool;1,312
1.6) By origin of the funds: Foreign funds;Total;86,884
1.6) By origin of the funds: Foreign funds;Main;71,524
1.6) By origin of the funds: Foreign funds;Secondary dwellings;5,480
1.6) By origin of the funds: Foreign funds;Tool;9,880
Purchase of R&D services in biotechnology (thousands of euros);Total;145,440
Purchase of R&D services in biotechnology (thousands of euros);Main;107,282
Purchase of R&D services in biotechnology (thousands of euros);Secondary dwellings;14,145
Purchase of R&D services in biotechnology (thousands of euros);Tool;24,013
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;95,870
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Main;75,671
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Secondary dwellings;12,772
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Tool;7,428
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;49,570
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Main;31,611
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Secondary dwellings;1,374
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Tool;16,585
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;39.8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Main;48.6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Secondary dwellings;37.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Tool;28.9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;12.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Main;11.4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Secondary dwellings;15.6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Tool;12.7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;18.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Main;20.9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Secondary dwellings;20.6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Tool;14.4
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;11.2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Main;10.5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Secondary dwellings;15.2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Tool;10.7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;15.6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Main;16.0
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Secondary dwellings;25.4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Tool;11.3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;16.5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Main;19.0
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Secondary dwellings;21.4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Tool;11.5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;16.1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Main;16.4
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Secondary dwellings;23.8
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Tool;12.7
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;40.0
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Main;47.3
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Secondary dwellings;42.8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Tool;29.4
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;53.9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Main;62.7
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Secondary dwellings;54.5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Tool;41.9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;21.5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Main;23.6
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Secondary dwellings;26.1
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Tool;16.9
% Companies with income of an international origin related to biotechnological activities;Total;22.2
% Companies with income of an international origin related to biotechnological activities;Main;29.9
% Companies with income of an international origin related to biotechnological activities;Secondary dwellings;15.4
% Companies with income of an international origin related to biotechnological activities;Tool;14.7
% Turnover representing income of an international origin related to biotechnological activities;Total;1.9
% Turnover representing income of an international origin related to biotechnological activities;Main;13.4
% Turnover representing income of an international origin related to biotechnological activities;Secondary dwellings;0.1
% Turnover representing income of an international origin related to biotechnological activities;Tool;1.5
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;65.5
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Main;67.7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Secondary dwellings;57.0
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Tool;60.1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;34.5
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Main;32.3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Secondary dwellings;43.0
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Tool;39.9
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;86.3
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Main;82.7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Secondary dwellings;91.3
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Tool;96.5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;12.2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;16.4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary dwellings;1.2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool;0.9
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1.1
% Income of an international origin related with activities according to the classification: Operating source abroad;Main;0.8
% Income of an international origin related with activities according to the classification: Operating source abroad;Secondary dwellings;7.5
% Income of an international origin related with activities according to the classification: Operating source abroad;Tool;1.3
% Income of an international origin related with activities according to the classification: Other;Total;0.4
% Income of an international origin related with activities according to the classification: Other;Main;0.1
% Income of an international origin related with activities according to the classification: Other;Secondary dwellings;0.0
% Income of an international origin related with activities according to the classification: Other;Tool;1.3